Protalix BioTherapeutics, Inc. (Company) The Bank of New York Mellon Trust Company, N.A., as Trustee (Trustee) INDENTURE Dated as of July 24, 2017Indenture • July 25th, 2017 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of July 24, 2017, between Protalix BioTherapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., as trustee, conversion agent, registrar and paying agent (in such capacities, the “Trustee,” “Conversion Agent,” “Registrar” and “Paying Agent,” respectively).
EXCHANGE AGREEMENT by and among Protalix BioTherapeutics, Inc. and the Parties Signatory Hereto Dated as of July 24, 2017Exchange Agreement • July 25th, 2017 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
EXCHANGE AGREEMENT dated as of July 24, 2017 (this “Agreement”), by and among Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), and the parties signatory hereto (each, a “Purchaser,” and collectively, the “Purchasers”).
FIRST Supplemental IndentureFirst Supplemental Indenture • July 25th, 2017 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of July 24, 2017 (this “First Supplemental Indenture”), between PROTALIX BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), as issuer, the Guarantors party hereto, and The Bank of New York Mellon Trust Company, N.A., as Trustee, registrar, paying agent and conversion agent, and Wilmington Savings Fund Society, FSB, as the Collateral Agent, under an Indenture, dated as of December 7, 2016, by and among the Company, each of the guarantors party thereto, Wilmington Savings Fund Society, FSB, as collateral agent, and the Trustee (the “Base Indenture”). All capitalized terms used in this First Supplemental Indenture and not otherwise defined herein have the meanings given to the terms in the Base Indenture.
NOTE PURCHASE AGREEMENTNote Purchase Agreement • July 25th, 2017 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Note Purchase Agreement (this “Agreement”) is made as of July 24, 2017, by and among Protalix BioTherapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and each purchaser identified on the signature pages hereof (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). Each Purchaser hereby confirms its agreement with you as follows:
